What is she best known for?
The fields of study she is best known for:
- Cancer
- Gene
- Internal medicine
Her primary areas of study are Immunology, Internal medicine, Melanoma, Cancer and Oncology.
Her work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine.
Her study in Melanoma is interdisciplinary in nature, drawing from both Interleukin 2 and Renal cell carcinoma.
Her study in Immunotherapy and Melanoma Vaccine is done as part of Cancer.
Suzanne L. Topalian has included themes like Pembrolizumab, Progressive disease, Pancreatic cancer and Pathology in her Oncology study.
Her work carried out in the field of Lung cancer brings together such families of science as Colorectal cancer, Prostate cancer and Biopsy.
Her most cited work include:
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8605 citations)
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (5480 citations)
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2498 citations)
What are the main themes of her work throughout her whole career to date?
Suzanne L. Topalian focuses on Immunology, Melanoma, Internal medicine, Cancer research and Immunotherapy.
Her research ties Cancer and Immunology together.
As part of one scientific family, Suzanne L. Topalian deals mainly with the area of Melanoma, narrowing it down to issues related to the Tumor-infiltrating lymphocytes, and often Cytokine secretion and Cyclophosphamide.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Surgery and Oncology.
The various areas that Suzanne L. Topalian examines in her Cancer research study include CD20, MHC class I, FOXP3 and Cancer immunotherapy.
The Immunotherapy study combines topics in areas such as T lymphocyte, Adoptive cell transfer, Metastasis, Interleukin 2 and Lymphokine-activated killer cell.
She most often published in these fields:
- Immunology (41.95%)
- Melanoma (35.59%)
- Internal medicine (33.05%)
What were the highlights of her more recent work (between 2017-2021)?
- Cancer research (28.39%)
- Oncology (25.85%)
- Internal medicine (33.05%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Cancer research, Oncology, Internal medicine, Immunotherapy and Nivolumab.
Her Cancer research research includes themes of Blockade and Immune system, FOXP3.
Her Immune system study integrates concerns from other disciplines, such as Antigen and B cell.
Her Oncology research is multidisciplinary, relying on both Stage, Biopsy, Pembrolizumab and Autopsy.
Her study on Immunotherapy is covered under Cancer.
Her Nivolumab research integrates issues from Neoadjuvant therapy, Major Pathologic Response, Clinical trial, Carcinoma and Lung cancer.
Between 2017 and 2021, her most popular works were:
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (786 citations)
- Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab (187 citations)
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy (165 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Her scientific interests lie mostly in Nivolumab, Internal medicine, Oncology, Cancer research and Carcinoma.
Her studies deal with areas such as Clinical trial and Melanoma as well as Nivolumab.
Her research in Melanoma intersects with topics in Odds ratio, Progressive disease and Renal cell carcinoma.
She is studying Progression-free survival, which is a component of Internal medicine.
Her Cancer research research incorporates themes from Merkel cell carcinoma and Immune system.
Her Ipilimumab study combines topics in areas such as Immune checkpoint and Blockade.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
